Abstract
Changes in expression and dysfunctional signaling of TrkA/B/C receptors and oncogenic Trk fusion proteins are found in neurological diseases and cancers. Here, we describe the development of a first F-18-labeled optimized lead suitable for in vivo imaging of Trk, [F-18]TRACK, which is radiosynthesized with ease from a nonactivated aryl precursor concurrently combining largely reduced P-gp liability and improved brain kinetics compared to previous leads while displaying high on-target affinity and human kinome selectivity.
Item Type: | Journal article |
---|---|
Faculties: | Medicine |
Subjects: | 600 Technology > 610 Medicine and health |
ISSN: | 0022-2623 |
Language: | English |
Item ID: | 63184 |
Date Deposited: | 19. Jul 2019, 12:12 |
Last Modified: | 04. Nov 2020, 13:41 |